These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18630504)

  • 1. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer.
    Hoffmann K; Mehrle S; Schmidt J; Büchler MW; Märten A
    Anticancer Res; 2008; 28(3A):1499-507. PubMed ID: 18630504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of an anticancer activity of combination of interferon-alpha and gemcitabine on pancreatic cancer cells.
    Isayev O; Sokolova DV; Anisimova NY; Spirina TS; Gasimov E
    J Cancer Res Ther; 2024 Jul; 20(5):1494-1498. PubMed ID: 39412913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
    Shi X; Liu S; Kleeff J; Friess H; Büchler MW
    Oncology; 2002; 62(4):354-62. PubMed ID: 12138244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
    Xu H; Li Y; Paxton JW; Wu Z
    Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
    Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
    Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
    Qiu F; Chen J; Cao J; Diao F; Huang P
    Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
    Michienzi S; Bucci B; Verga Falzacappa C; Patriarca V; Stigliano A; Panacchia L; Brunetti E; Toscano V; Misiti S
    J Endocrinol; 2007 May; 193(2):209-23. PubMed ID: 17470512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
    Dineen SP; Roland CL; Greer R; Carbon JG; Toombs JE; Gupta P; Bardeesy N; Sun H; Williams N; Minna JD; Brekken RA
    Cancer Res; 2010 Apr; 70(7):2852-61. PubMed ID: 20332237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
    Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
    Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
    Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.